Peter Cox is Vice President of Drug Discovery, responsible for leading BenevolentAI’s efforts to discover new therapeutic targets in neurodegenerative diseases using the Benevolent Platform™. He also leads a team of drug discovery scientists that provide biology, toxicology and safety expertise across a diverse range of BenevolentAI’s drug discovery programmes, helping teams to make the right data-driven decisions, be they for target validation or drug discovery project progression.
Peter has 23 years of experience in drug discovery. Before joining BenevolentAI, he spent 16 years at Pfizer in preclinical drug discovery, leading and supporting projects targeting ion channels, enzymes, transporters and G-protein coupled receptors (GPCRs) for the treatment of chronic pain. Here, Peter was part of a team that confirmed the molecular nature of the target for Neurontin (gabapentin) and Lyrica (pregabalin), both key treatments for chronic neuropathic pain. Peter completed postdoctoral training in neuroscience at INSERM, France, and the University of Cambridge and obtained a PhD in Virology from the University of Glasgow.